

# SlgN Immunology Seminar



## Prof Sergio Lira

Mount Sinai School of Medicine, New York, USA

### Inflammation, microbiota and intestinal neoplasia: emerging concepts

#### Host

Dr Maria Lafaille  
Singapore Immunology  
Network, A\*Star

#### Date

Monday,  
18 June 2012

#### Time

11.00am – 12.00pm

#### Venue

SlgN Seminar Room,  
Immunos Building  
Level 4  
Biopolis

Epithelial cancers are often initiated by activating mutations of components of the MAPK pathway such as *BRAF*, *KRAS* or *EGFR*. Human intestinal serrated polyps frequently harbor activating mutations in *BRAF* or *KRAS*, but the role of *EGFR* is unclear. We report that *EGFR* and *ERK1/2* phosphorylation is found in the absence of *KRAS* or *BRAF* activating mutations in a subset of a group of human serrated lesions called hyperplastic polyps. Expression of the *EGFR* ligand HB-EGF in the intestine of transgenic mice promoted development of small cecal serrated polyps. Mice expressing both HB-EGF and US28, a constitutively active chemokine receptor that increases processing of HB-EGF from the membrane, rapidly developed large cecal serrated polyps that resembled human hyperplastic polyps. These polyps, similar to human polyps, showed increased *EGFR* and *ERK1/2* phosphorylation within serrated epithelium. Treatment of the transgenic animals with pharmacological inhibitors of *EGFR* or MAP kinase, as well as with antibiotics significantly reduced polyp development. These results suggest an important role for *EGFR* signaling and the microbiota in the development of serrated polyps.